TSH suppression by octreotide in differentiated thyroid carcinoma

Abstract

OBJECTIVE This study evaluates the addition of octreotide and L-thyroxine to shorten the perlod of exposure to unduly elevated TSH levels in patients with differentiated thyroid carcinoma undergoing total body scan with '% DESIGN Fourteen thyroldectomized patients were studied after total body scan and the restarting of dlfferent doses of thyroxlne. After one year a second total body scan and a schedule of the same dose of thyroxine combined with octreotide were performed In each subject. PATIENTS Patients were divided into four groups according to the treatment seven patients recelved initlaily 100 pg of L-thyroxine (Group 1) and after 1 year 100 pg of L-thyroxine plus 300 pg of octreotidelday (Group 3): the other seven received lnitiaily 150 pg of L-thyroxine (Group 2) and then 150 pg of L-thyroxine plus 300 pg of octreotldel day (Group 4).MEASUREMENTS Serum TSH, T3 and T4 were measured on the day of radlolodine administration (day 0) and after 14,21,30,45,60 and 90 days.